10x Genomics Inc (TXG)

$28.95

-0.21

(-0.72%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on 10x Genomics Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 134.28M → 183.97M (in $), with an average increase of 9.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -92.98M → -48.95M (in $), with an average increase of 90.0% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 37.0% return, outperforming this stock by 83.5%

  • Vs HQY

    In the last 3 years, Healthequity Inc has given 12.5% return, outperforming this stock by 97.5%

Performance

  • $27.36
    $29.23
    $28.95
    downward going graph

    5.49%

    Downside

    Day's Volatility :6.4%

    Upside

    0.96%

    downward going graph
  • $28.95
    $63.57
    $28.95
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :54.46%

    Upside

    54.46%

    downward going graph

Returns

Period10x Genomics IncSector (Health Care)Index (Russel 2000)
3 Months
-30.59%
-0.7%
0.0%
6 Months
-26.51%
6.6%
0.0%
1 Year
-46.48%
3.7%
-1.5%
3 Years
-84.4%
14.0%
-21.8%

Highlights

Market Capitalization
3.9B
Book Value
$6.22
Earnings Per Share (EPS)
-2.18
Wall Street Target Price
57.07
Profit Margin
-41.23%
Operating Margin TTM
-15.76%
Return On Assets TTM
-12.22%
Return On Equity TTM
-32.98%
Revenue TTM
618.7M
Revenue Per Share TTM
5.28
Quarterly Revenue Growth YOY
17.8%
Gross Profit TTM
396.0M
EBITDA
-159.4M
Diluted Eps TTM
-2.18
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.59
EPS Estimate Next Year
-0.94
EPS Estimate Current Quarter
-0.36
EPS Estimate Next Quarter
-0.46

Analyst Recommendation

Buy
    66%Buy
    22%Hold
    11%Sell
Based on 18 Wall street analysts offering stock ratings for 10x Genomics Inc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
4
4
4
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 97.13%

Current $28.95
Target $57.07

Company Financials

FY18Y/Y Change
Revenue
146.3M
↑ 105.83%
Net Income
-112.5M
↑ 499.54%
Net Profit Margin
-76.88%
↓ 50.49%
FY19Y/Y Change
Revenue
245.9M
↑ 68.06%
Net Income
-31.3M
↓ 72.22%
Net Profit Margin
-12.71%
↑ 64.17%
FY20Y/Y Change
Revenue
298.8M
↑ 21.53%
Net Income
-542.7M
↑ 1636.68%
Net Profit Margin
-181.61%
↓ 168.9%
FY21Y/Y Change
Revenue
490.5M
↑ 64.13%
Net Income
-58.2M
↓ 89.27%
Net Profit Margin
-11.87%
↑ 169.74%
FY22Y/Y Change
Revenue
516.4M
↑ 5.28%
Net Income
-166.0M
↑ 185.11%
Net Profit Margin
-32.15%
↓ 20.28%
FY23Y/Y Change
Revenue
618.7M
↑ 19.81%
Net Income
-255.1M
↑ 53.67%
Net Profit Margin
-41.23%
↓ 9.08%
Q3 FY22Q/Q Change
Revenue
131.1M
↑ 14.36%
Net Income
-41.9M
↓ 34.97%
Net Profit Margin
-31.98%
↑ 24.26%
Q4 FY22Q/Q Change
Revenue
156.2M
↑ 19.2%
Net Income
-17.2M
↓ 58.93%
Net Profit Margin
-11.02%
↑ 20.96%
Q1 FY23Q/Q Change
Revenue
134.3M
↓ 14.05%
Net Income
-50.7M
↑ 194.78%
Net Profit Margin
-37.79%
↓ 26.77%
Q2 FY23Q/Q Change
Revenue
146.8M
↑ 9.33%
Net Income
-62.4M
↑ 22.99%
Net Profit Margin
-42.51%
↓ 4.72%
Q3 FY23Q/Q Change
Revenue
153.6M
↑ 4.65%
Net Income
-93.0M
↑ 48.98%
Net Profit Margin
-60.52%
↓ 18.01%
Q4 FY23Q/Q Change
Revenue
184.0M
↑ 19.74%
Net Income
-49.0M
↓ 47.36%
Net Profit Margin
-26.61%
↑ 33.91%
FY18Y/Y Change
Total Assets
124.3M
↑ 64.41%
Total Liabilities
344.3M
↑ 83.02%
FY19Y/Y Change
Total Assets
605.9M
↑ 387.43%
Total Liabilities
185.8M
↓ 46.02%
FY20Y/Y Change
Total Assets
929.3M
↑ 53.38%
Total Liabilities
190.3M
↑ 2.38%
FY21Y/Y Change
Total Assets
1.0B
↑ 9.63%
Total Liabilities
201.3M
↑ 5.78%
FY22Y/Y Change
Total Assets
1.0B
↑ 1.0%
Total Liabilities
223.2M
↑ 10.92%
FY23Y/Y Change
Total Assets
965.1M
↓ 6.2%
Total Liabilities
224.1M
↑ 0.39%
Q3 FY22Q/Q Change
Total Assets
996.2M
↓ 0.54%
Total Liabilities
220.4M
↑ 1.07%
Q4 FY22Q/Q Change
Total Assets
1.0B
↑ 3.29%
Total Liabilities
223.2M
↑ 1.28%
Q1 FY23Q/Q Change
Total Assets
1.0B
↓ 1.45%
Total Liabilities
211.6M
↓ 5.19%
Q2 FY23Q/Q Change
Total Assets
989.6M
↓ 2.41%
Total Liabilities
196.3M
↓ 7.23%
Q3 FY23Q/Q Change
Total Assets
948.5M
↓ 4.15%
Total Liabilities
203.3M
↑ 3.56%
Q4 FY23Q/Q Change
Total Assets
965.1M
↑ 1.75%
Total Liabilities
224.1M
↑ 10.22%
FY18Y/Y Change
Operating Cash Flow
-76.4M
↑ 614.17%
Investing Cash Flow
-6.7M
↑ 78.62%
Financing Cash Flow
105.4M
↑ 411.91%
FY19Y/Y Change
Operating Cash Flow
34.6M
↓ 145.32%
Investing Cash Flow
-42.8M
↑ 537.46%
Financing Cash Flow
414.6M
↑ 293.47%
FY20Y/Y Change
Operating Cash Flow
-217.9M
↓ 729.27%
Investing Cash Flow
-38.4M
↓ 10.23%
Financing Cash Flow
468.9M
↑ 13.1%
FY21Y/Y Change
Operating Cash Flow
-21.4M
↓ 90.19%
Investing Cash Flow
-106.7M
↑ 177.98%
Financing Cash Flow
35.3M
↓ 92.47%
FY22Y/Y Change
Operating Cash Flow
-33.6M
↑ 57.24%
Investing Cash Flow
-350.9M
↑ 228.76%
Financing Cash Flow
15.8M
↓ 55.19%
Q3 FY22Q/Q Change
Operating Cash Flow
-9.6M
↓ 43.62%
Investing Cash Flow
-32.6M
↑ 18.54%
Financing Cash Flow
2.0M
↓ 67.94%
Q4 FY22Q/Q Change
Operating Cash Flow
13.7M
↓ 243.49%
Investing Cash Flow
-33.2M
↑ 1.66%
Financing Cash Flow
5.0M
↑ 145.27%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.1M
↓ 130.06%
Investing Cash Flow
120.0M
↓ 461.62%
Financing Cash Flow
-3.4M
↓ 168.27%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.5M
↑ 179.42%
Investing Cash Flow
-4.5M
↓ 103.72%
Financing Cash Flow
7.1M
↓ 307.85%
Q3 FY23Q/Q Change
Operating Cash Flow
-25.3M
↑ 119.54%
Investing Cash Flow
4.9M
↓ 209.82%
Financing Cash Flow
4.4M
↓ 38.36%

Technicals Summary

Sell

Neutral

Buy

10x Genomics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
10x Genomics Inc
10x Genomics Inc
-19.18%
-26.51%
-46.48%
-84.4%
-44.72%
Solventum Corp
Solventum Corp
-10.64%
-10.64%
-10.64%
-10.64%
-10.64%
Veeva Systems Inc.
Veeva Systems Inc.
-12.8%
-3.39%
8.83%
-26.33%
55.83%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-5.98%
30.6%
1.83%
40.83%
40.83%
Healthequity Inc
Healthequity Inc
-3.72%
6.22%
37.05%
12.91%
23.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
10x Genomics Inc
10x Genomics Inc
NA
NA
NA
-1.59
-0.33
-0.12
NA
6.22
Solventum Corp
Solventum Corp
NA
NA
NA
0.0
0.12
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
62.03
62.03
1.35
4.76
0.13
0.05
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
28.08
28.08
20.11
4.3
0.19
0.06
0.0
15.67
Healthequity Inc
Healthequity Inc
125.42
125.42
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
10x Genomics Inc
10x Genomics Inc
Buy
$3.9B
-44.72%
NA
-41.23%
Solventum Corp
Solventum Corp
NA
$11.7B
-10.64%
NA
16.42%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.3B
55.83%
62.03
22.24%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.0B
40.83%
28.08
8.02%
Healthequity Inc
Healthequity Inc
Buy
$6.9B
23.47%
125.42
5.57%

Institutional Holdings

  • FMR Inc

    10.73%

  • Vanguard Group Inc

    7.56%

  • Baillie Gifford & Co Limited.

    6.65%

  • BlackRock Inc

    4.79%

  • Morgan Stanley - Brokerage Accounts

    3.51%

  • ARK Investment Management LLC

    3.39%

Corporate Announcements

  • 10x Genomics Inc Earnings

    10x Genomics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

advancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.

Organization
10x Genomics Inc
Employees
1259
CEO
Dr. Serge Saxonov Ph.D.
Industry
Commercial Services

Discover More

FAQs